Omehil 40 mg (Capsule (Enteric Coated))

Unit Price: ৳ 7.00 (3 x 10: ৳ 210.00)

Strip Price: ৳ 70.00

Medicine Details

Category	Details
Generic	Omeprazole
Company	Goodman pharmaceuticals ltd
Also available as	Omehil 20 mg capsule

Gastric and duodenal ulcer
NSAID-associated duodenal and gastric ulcer
Prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
Gastro-esophageal reflux disease
Long-term management of acid reflux disease
Acid-related dyspepsia
Severe ulcerating reflux esophagitis
Prophylaxis of acid aspiration during general anesthesia
Zollinger-Ellison syndrome
Helicobacter pylori-induced peptic ulcer

Inhibitor of gastric acid secretion
Blocker of hydrogen-potassium-adenosine triphosphatase (H+/K+ ATPase) enzyme system
Onset of antisecretory effect within one hour
Maximum effect occurring within two hours
Inhibition of secretion lasting up to 72 hours
Gradual return of secretory activity over 3 to 5 days after discontinuation

20 mg once daily for 4 weeks in duodenal ulceration
40 mg daily in severe or recurrent cases of gastric ulceration
Maintenance dose for recurrent duodenal ulcer, 20 mg once daily
40 mg once daily for 4 weeks in gastro-esophageal reflux disease
10-20 mg daily for long-term management of acid reflux disease
10-20 mg once daily for 2-4 weeks in acid-related dyspepsia
40 mg on the preceding evening and 2-6 hours before surgery for prophylaxis of acid aspiration
Initially 60 mg once daily for Zollinger-Ellison syndrome
Omeprazole recommended at a dose of 20 mg twice daily for Helicobacter pylori eradication regimen in peptic ulcer disease
Pediatric use: 10-20 mg once daily for 4-12 weeks (if body-weight 10-20 kg), 20-40 mg once daily for 4-12 weeks (if body-weight over 20 kg)

Intravenous administration only
IV injection should be given as a slow intravenous injection
IV infusion should be given over a period of 20-30 minutes or more
Reconstituted solution should be used within 4 hours (IV injection) or 12 hours (IV infusion)
Reconstituted solution should not be mixed or co-administered with any other drug

Reduced absorption of ketoconazole during treatment
Metabolized in the liver through cytochrome P450
Possible delay in the elimination of diazepam, phenytoin, and warfarin
Monitoring of patients receiving warfarin or phenytoin recommended
Increased plasma concentrations of Omeprazole and clarithromycin during concomitant administration

No adverse effects on pregnancy or on the health of the fetus/newborn child based on epidemiological studies
No information available on the passage of omeprazole into breast milk or its effects on the neonate
Discontinuation of breastfeeding if the use of omeprazole is considered essential

Avoid concomitant use of clopidogrel and omeprazole
Possible association of PPI therapy with increased risk for osteoporosis-related fractures
Atrophic gastritis noted occasionally in patients treated long-term with omeprazole
Concomitant use of PPIs with methotrexate may lead to methotrexate toxicities